More than 50 percent of the top 100 life sciences companies leverage real-world data to demonstrate their product’s value and differentiation to payers. Real-world access and therapy adherence often differ from clinical trials. Therefore, real-world data plays an important role in assessing these factors, which contribute to the overall effectiveness of the therapy.
In this webinar, the featured speakers will share a case study from Pfizer on using real-world data to assess medication adherence to tafamidis, a first-in-class drug for patients with heart disease caused by transthyretin amyloid cardiomyopathy (ATTR-CM). Pfizer leveraged claims data and clinical informatics to understand differences in regimen, access and length of adherence after launch. This provided them with a better understanding of the factors that contribute to adherence, opportunities for educational interventions and justification of value to payers.
Register for this webinar to understand the different aspects of medication and therapy adherence between real-world and clinical trials.
Bhash Parasuraman, PhD, VP, Patient and Health Impact, Internal Medicine and Rare Disease BUs, Pfizer
Bhash Parasuraman, PhD, is Vice President for Launch Excellence for the Gene Therapy Business at Pfizer. She plays a key strategic role in decision making and direction setting to optimize value, access and launch for Pfizer’s gene therapies from a global, regional and local perspective.
Bhash has 25 plus years of experience in the pharmaceutical and healthcare industries in health economics and outcomes research, epidemiology, medical affairs, commercial, pricing and market access. She has led large, cross functional, complex global and regional teams to enable delivery of robust evidence and access strategies for several primary and specialty care innovative medicines across the world. Her experience spans across several disease areas in respiratory, inflammation, oncology, cardiovascular, pain and neuroscience, rare diseases and in early and late-stage development.
Prior to joining Pfizer, Bhash was at AstraZeneca Pharmaceuticals for over 13 years where she held positions of increasing responsibility and leadership in their global clinical and commercial organizations. Bhash has played a leading role in several industry-specific collaborations, such as, representing the biopharma industry on the FDA-Critical Path Institute Patient Reported Outcomes Consortium Coordinating Committee and at various ISPOR Consortia and Round Tables. Bhash has presented extensively at professional conferences and published in several peer-reviewed journals.
Bhash’s previous experiences were at Johnson and Johnson in their global Health Economics group and at Blue Cross Blue Shield of North Carolina. Bhash has an undergraduate degree in pharmacy from Birla institute of Technology, India, and a doctoral degree in pharmacy administration from University of Louisiana, US.
Sapna Prasad, PhD, Senior Director, Clarify Insights, Clarify Health
Sapna brings over 10 years of experience working with different healthcare organizations in pharmacoeconomic and biomedical research. At Clarify, Sapna leads the clinical informatics team, with responsibility for delivering data-driven advanced analytics to Clarify’s payer, provider and life sciences customers. While at Clarify, Sapna has played an instrumental role as a subject matter expert in health economics and outcomes research and informatics, helping to grow the Life Sciences business. Prior to Clarify, Sapna was the Pharmacoeconomic Specialist at Yale Cancer Center, focused on building out data-driven health economics and outcomes research programs in oncology. Sapna was also a member of Optum’s HEOR team focused on building economic models in support of regulatory submissions in the US and Canada.
Sapna holds a PhD in health economics from the University of Texas School of Public Health, an MSc in health, community and development from the London School of Economics and a BA from Baylor University in journalism and biology.
Who Should Attend?
This webinar is intended for HEOR, RWE, market access, business unit leaders, clinical operations and comparative effectiveness/research professionals.
What You Will Learn
Attendees will gain insights into:
- Designing and conducting a study to assess differences in medication adherence between real-world and clinical trial populations
- Overcoming data quality challenges and gaps in treatment data, leveraging clinical informatics
- Interpreting study results to understand differences in adherence based on demographic and clinical characteristics
Clarify Health is an enterprise analytics and value-based payments platform company that empowers life sciences companies, payers, and providers to deliver better care, therapies, and outcomes with actionable patient journey insights. Life sciences companies use Clarify’s cloud-based software for healthcare analytics and real-world evidence (RWE) to accelerate patient recruitment for clinical trials and drive faster brand adoption at launch and beyond. It delivers on-demand insights with unprecedented speed and precision. Clarify was acclaimed by Frost & Sullivan as the most innovative RWE solution in the life sciences industry in 2021. Learn more at clarifyhealth.com.